ABSTRACT
BACKGROUND: Fluoroquinolones and rifampicin are antibiotics frequently used for the treatment of osteoarticular infections, and their therapeutic drug monitoring is recommended. The aim of this study was to develop and validate a rapid and selective method of simultaneous quantification of levofloxacin, ciprofloxacin, moxifloxacin and rifampicin with short pretreatment and run times in order to be easily used in clinical practice. METHODS: After a simple protein precipitation of plasma samples, the chromatographic separation was performed using an ultra-performance liquid chromatography system coupled with mass tandem spectrometry in a positive ionization mode. The mobile phase consisted of a gradient elution of water-formic acid (100:0.1, v/v)-ammonium acetate 2â¯mM (A) and methanol-formic acid (100:0.1, v/v)-ammonium acetate 2â¯mM (B) at a flow rate at 0.3â¯mL/min. RESULTS: Analysis time was 5â¯min per run, and all analytes and internal standards eluted within 0.85-1.69â¯minutes. The calibration curves were linear over the range from 0.5-30⯵g/mL for levofloxacin, ciprofloxacin, moxifloxacin and rifampicin with linear regression coefficients above 0.995 for all analytes. The intra-day and inter-day coefficients of variation were below 10 % for lower and higher concentration. This method was successfully applied to drug monitoring in patients with an osteoarticular infection. CONCLUSION: A simple, rapid, and selective liquid chromatography-tandem mass spectrometry method was developed and validated for the simultaneous quantification of levofloxacin, ciprofloxacin, moxifloxacin and rifampicin in human plasma.
Subject(s)
Chromatography, High Pressure Liquid/methods , Ciprofloxacin/blood , Levofloxacin/blood , Moxifloxacin/blood , Plasma/chemistry , Rifampin/blood , Tandem Mass Spectrometry/methods , Drug Monitoring/methods , Female , Humans , Limit of Detection , Male , Middle Aged , Reproducibility of ResultsABSTRACT
OBJECTIVE: There is considerable uncertainty regarding the optimal use of rifampicin for the treatment of tuberculous (TB) meningitis. A pharmacokinetic modeling and simulation study of rifampicin concentrations in cerebrospinal fluid (CSF) during TB meningitis treatment was performed in this study. METHODS: Parameters for rifampicin pharmacokinetics in CSF were estimated using individual-level rifampicin pharmacokinetic data, and the model was externally validated in three separate patient cohorts. Monte Carlo simulations of rifampicin serum and CSF concentrations were performed. The area under the rifampicin CSF concentration-versus-time curve during 24 h (AUC0-24) relative to the minimum inhibitory concentration (MIC) served as the pharmacodynamic target. RESULTS: Across all simulated patients on the first treatment day, 85% attained the target AUC0-24/MIC ratio of 30 under a weight-based dosing scheme approximating 10 mg/kg. At the rifampicin MIC of 0.5 mg/l, the probability of AUC0-24/MIC target attainment was 26%. With an intensified dosing strategy corresponding to 20 mg/kg, target attainment increased to 99%, including 93% with a MIC of 0.5 mg/l. CONCLUSIONS: Under standard dosing guidelines, few TB meningitis patients would be expected to attain therapeutic rifampicin exposures in CSF when the MIC is ≥0.5 mg/l. Either downward adjustment of the rifampicin MIC breakpoint in the context of TB meningitis, or intensified rifampicin dosing upwards of 20 mg/kg/day, would reflect the likelihood of pharmacodynamic target attainment in CSF.
Subject(s)
Antitubercular Agents/cerebrospinal fluid , Rifampin/cerebrospinal fluid , Tuberculosis, Meningeal/cerebrospinal fluid , Adult , Antitubercular Agents/blood , Antitubercular Agents/pharmacokinetics , Antitubercular Agents/therapeutic use , Humans , Microbial Sensitivity Tests , Monte Carlo Method , Rifampin/blood , Rifampin/pharmacokinetics , Tuberculosis, Meningeal/drug therapyABSTRACT
Objectives: We compared the pharmacokinetics of moxifloxacin during rifampicin co-treatment or when dosed alone in African patients with drug-susceptible recurrent TB. Methods: Patients in the intervention arm of the Improving Retreatment Success (IMPRESS) randomized controlled TB trial received 400â mg of moxifloxacin, with rifampicin, isoniazid and pyrazinamide in the treatment regimen. Moxifloxacin concentrations were measured in plasma during rifampicin-based TB treatment and again 4â weeks after treatment completion, when given alone as a single dose. Moxifloxacin concentration-time data were analysed using non-linear mixed-effects models. Results: We included 58 patients; 42 (72.4%) were HIV co-infected and 40 (95%) of these were on efavirenz-based ART. Moxifloxacin pharmacokinetics was best described using a two-compartment disposition model with first-order lagged absorption and elimination using a semi-mechanistic model describing hepatic extraction. Oral clearance (CL/F) of moxifloxacin during rifampicin-based TB treatment was 24.3â L/h for a typical patient (fat-free mass of 47â kg), resulting in an AUC of 16.5â mg·h/L. This exposure was 7.8% lower than the AUC following the single dose of moxifloxacin given alone after TB treatment completion. In HIV-co-infected patients taking efavirenz-based ART, CL/F of moxifloxacin was increased by 42.4%, resulting in a further 30% reduction in moxifloxacin AUC. Conclusions: Moxifloxacin clearance was high and plasma concentrations low in our patients overall. Moxifloxacin AUC was further decreased by co-administration of efavirenz-based ART and, to a lesser extent, rifampicin. The clinical relevance of the low moxifloxacin concentrations for TB treatment outcomes and the need for moxifloxacin dose adjustment in the presence of rifampicin and efavirenz co-treatment need further investigation.
Subject(s)
Antibiotics, Antitubercular/therapeutic use , Benzoxazines/therapeutic use , Fluoroquinolones/pharmacokinetics , HIV Infections/complications , Rifampin/therapeutic use , Tuberculosis, Pulmonary/complications , Tuberculosis, Pulmonary/drug therapy , Adult , Africa , Alkynes , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/therapeutic use , Antibiotics, Antitubercular/administration & dosage , Antibiotics, Antitubercular/adverse effects , Antibiotics, Antitubercular/pharmacokinetics , Benzoxazines/administration & dosage , Benzoxazines/blood , Coinfection/drug therapy , Coinfection/microbiology , Coinfection/virology , Cyclopropanes , Drug Interactions , Drug Therapy, Combination , Female , Fluoroquinolones/administration & dosage , Fluoroquinolones/blood , Fluoroquinolones/therapeutic use , HIV Infections/drug therapy , HIV Infections/virology , Humans , Male , Moxifloxacin , Reverse Transcriptase Inhibitors/administration & dosage , Reverse Transcriptase Inhibitors/adverse effects , Reverse Transcriptase Inhibitors/therapeutic use , Rifampin/administration & dosage , Rifampin/adverse effects , Rifampin/blood , Tuberculosis, Pulmonary/metabolism , Tuberculosis, Pulmonary/microbiologyABSTRACT
BACKGROUND: There is scant evidence to support target drug exposures for optimal tuberculosis outcomes. We therefore assessed whether pharmacokinetic/pharmacodynamic (PK/PD) parameters could predict 2-month culture conversion. METHODS: One hundred patients with pulmonary tuberculosis (65% human immunodeficiency virus coinfected) were intensively sampled to determine rifampicin, isoniazid, and pyrazinamide plasma concentrations after 7-8 weeks of therapy, and PK parameters determined using nonlinear mixed-effects models. Detailed clinical data and sputum for culture were collected at baseline, 2 months, and 5-6 months. Minimum inhibitory concentrations (MICs) were determined on baseline isolates. Multivariate logistic regression and the assumption-free multivariate adaptive regression splines (MARS) were used to identify clinical and PK/PD predictors of 2-month culture conversion. Potential PK/PD predictors included 0- to 24-hour area under the curve (AUC0-24), maximum concentration (Cmax), AUC0-24/MIC, Cmax/MIC, and percentage of time that concentrations persisted above the MIC (%TMIC). RESULTS: Twenty-six percent of patients had Cmax of rifampicin <8 mg/L, pyrazinamide <35 mg/L, and isoniazid <3 mg/L. No relationship was found between PK exposures and 2-month culture conversion using multivariate logistic regression after adjusting for MIC. However, MARS identified negative interactions between isoniazid Cmax and rifampicin Cmax/MIC ratio on 2-month culture conversion. If isoniazid Cmax was <4.6 mg/L and rifampicin Cmax/MIC <28, the isoniazid concentration had an antagonistic effect on culture conversion. For patients with isoniazid Cmax >4.6 mg/L, higher isoniazid exposures were associated with improved rates of culture conversion. CONCLUSIONS: PK/PD analyses using MARS identified isoniazid Cmax and rifampicin Cmax/MIC thresholds below which there is concentration-dependent antagonism that reduces 2-month sputum culture conversion.
Subject(s)
Antitubercular Agents/therapeutic use , Coinfection/drug therapy , HIV Infections/complications , Mycobacterium tuberculosis/drug effects , Tuberculosis, Pulmonary/complications , Tuberculosis, Pulmonary/drug therapy , Adult , Antitubercular Agents/pharmacokinetics , Antitubercular Agents/pharmacology , Coinfection/microbiology , Coinfection/virology , Drug Interactions , Drug Therapy, Combination , Female , Humans , Isoniazid/antagonists & inhibitors , Isoniazid/pharmacokinetics , Isoniazid/pharmacology , Isoniazid/therapeutic use , Logistic Models , Male , Microbial Sensitivity Tests , Middle Aged , Mycobacterium tuberculosis/growth & development , Mycobacterium tuberculosis/isolation & purification , Mycobacterium tuberculosis/physiology , Pyrazinamide/administration & dosage , Pyrazinamide/blood , Pyrazinamide/pharmacokinetics , Pyrazinamide/pharmacology , Rifampin/blood , Rifampin/pharmacokinetics , Rifampin/pharmacology , Rifampin/therapeutic use , Sputum/microbiology , Treatment Outcome , Tuberculosis, Pulmonary/microbiologyABSTRACT
INTRODUCTION: Tuberculosis (TB) remains one of the world's deadliest communicable diseases. Although cure rates of the standard four-drug (rifampicin, isoniazid, pyrazinamide, ethambutol) treatment schedule can be as high as 95-98 % under clinical trial conditions, success rates may be much lower in less well resourced countries. Unsuccessful treatment with these first-line anti-TB drugs may lead to the development of multidrug resistant and extensively drug resistant TB. The intrinsic interindividual variability in the pharmacokinetics (PK) of the first-line anti-TB drugs is further exacerbated by co-morbidities such as HIV infection and diabetes. METHODS: Therapeutic drug monitoring has been proposed in an attempt to optimize treatment outcome and reduce the development of drug resistance. Several studies have shown that maximum plasma concentrations (C max), especially of rifampicin and isoniazid, are well below the proposed target C max concentrations in a substantial fraction of patients being treated with the standard four-drug treatment schedule, even though treatment's success rate in these studies was typically at least 85 %. DISCUSSION: The proposed target C max concentrations are based on the concentrations of these agents achieved in healthy volunteers and patients receiving the standard doses. Estimation of C max based on one or two sampling times may not have the necessary accuracy since absorption rate, especially for rifampicin, may be highly variable. In addition, minimum inhibitory concentration (MIC) variability should be taken into account to set clinically meaningful susceptibility breakpoints. Clearly, there is a need to better define the key target PK and pharmacodynamic (PD) parameters for therapeutic drug monitoring (TDM) of the first-line anti-TB drugs to be efficacious, C max (or area under the curve (AUC)) and C max/MIC (or AUC/MIC). CONCLUSION: Although TDM of first-line anti-TB drugs has been successfully used in a limited number of specialized centers to improve treatment outcome in slow responders, a better characterization of the target PK and/or PK/PD parameters is in our opinion necessary to make it cost-effective.
Subject(s)
Antitubercular Agents/therapeutic use , Drug Monitoring , Tuberculosis/drug therapy , Antitubercular Agents/blood , Antitubercular Agents/pharmacokinetics , Antitubercular Agents/pharmacology , Ethambutol/blood , Ethambutol/pharmacokinetics , Ethambutol/pharmacology , Ethambutol/therapeutic use , Humans , Isoniazid/blood , Isoniazid/pharmacokinetics , Isoniazid/pharmacology , Isoniazid/therapeutic use , Microbial Sensitivity Tests , Mycobacterium tuberculosis/drug effects , Pyrazinamide/blood , Pyrazinamide/pharmacokinetics , Pyrazinamide/pharmacology , Pyrazinamide/therapeutic use , Rifampin/blood , Rifampin/pharmacokinetics , Rifampin/pharmacology , Rifampin/therapeutic use , Treatment OutcomeABSTRACT
There are limited pharmacokinetic data for use of the first-line antituberculosis drugs during infancy (<12 months of age), when drug disposition may differ. Intensive pharmacokinetic sampling was performed in infants routinely receiving antituberculosis treatment, including rifampin, isoniazid, pyrazinamide, and ethambutol, using World Health Organization-recommended doses. Regulatory-approved single-drug formulations, including two rifampin suspensions, were used on the sampling day. Assays were conducted using liquid chromatography-mass spectrometry; pharmacokinetic parameters were generated using noncompartmental analysis. Thirty-nine infants were studied; 14 (36%) had culture-confirmed tuberculosis. Fifteen (38%) were premature (<37 weeks gestation); 5 (13%) were HIV infected. The mean corrected age and weight were 6.6 months and 6.45 kg, respectively. The mean maximum plasma concentrations (Cmax) for rifampin, isoniazid, pyrazinamide, and ethambutol were 2.9, 7.9, 41.9, and 1.3 µg/ml, respectively (current recommended adult target concentrations: 8 to 24, 3 to 6, 20 to 50, and 2 to 6 µg/ml, respectively), and the mean areas under the concentration-time curves from 0 to 8 h (AUC0-8) were 12.1, 24.7, 239.4, and 5.1 µg · h/ml, respectively. After adjusting for age and weight, rifampin exposures for the two formulations used differed inCmax(geometric mean ratio [GMR],2.55; 95% confidence interval [CI], 1.47 to 4.41;P= 0.001) and AUC0-8(GMR, 2.52; 95% CI, 1.34 to 4.73;P= 0.005). HIV status was associated with lower pyrazinamideCmax(GMR, 0.85; 95% CI, 0.75 to 0.96;P= 0.013) and AUC0-8(GMR, 0.79; 95% CI, 0.69 to 0.90;P< 0.001) values. No other important differences were observed due to age, weight, prematurity, ethnicity, or gender. In summary, isoniazid and pyrazinamide concentrations in infants compared well with proposed adult target concentrations; ethambutol concentrations were lower but similar to previously reported pediatric studies. The low rifampin exposures require further investigation. (This study has been registered at ClinicalTrials.gov under registration no. NCT01637558.).
Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Ethambutol/pharmacokinetics , Isoniazid/pharmacokinetics , Mycobacterium tuberculosis/drug effects , Pyrazinamide/pharmacokinetics , Rifampin/pharmacokinetics , Tuberculosis, Pulmonary/drug therapy , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/therapeutic use , Area Under Curve , Coinfection , Drug Dosage Calculations , Ethambutol/blood , Ethambutol/therapeutic use , Female , HIV/drug effects , HIV/growth & development , HIV Infections/drug therapy , HIV Infections/virology , Humans , Infant , Infant, Newborn , Isoniazid/blood , Isoniazid/therapeutic use , Male , Microbial Sensitivity Tests , Mycobacterium tuberculosis/growth & development , Practice Guidelines as Topic , Pyrazinamide/blood , Pyrazinamide/therapeutic use , Rifampin/blood , Rifampin/therapeutic use , Tuberculosis, Pulmonary/blood , Tuberculosis, Pulmonary/microbiologyABSTRACT
Pediatric drug development is hampered by biological, clinical, and formulation challenges associated with age-based populations. A primary cause for this lack of development is the inability to accurately predict ontogenic changes that affect pharmacokinetics (PK) in children using traditional preclinical animal models. In response to this issue, our laboratory has conducted a proof-of-concept study to investigate the potential utility of juvenile pigs to serve as surrogates for children during preclinical PK testing of selected rifampin dosage forms. Pigs were surgically modified with jugular vein catheters that were externalized in the dorsal scapular region and connected to an automated blood sampling system (PigTurn-Culex-L). Commercially available rifampin capsules were administered to both 20 and 40 kg pigs to determine relevant PK parameters. Orally disintegrating tablet formulations of rifampin were also developed and administered to 20 kg pigs. Plasma samples were prepared from whole blood by centrifugation and analyzed for rifampin content by liquid chromatography-tandem mass spectrometry. Porcine PK parameters were determined from the resultant plasma-concentration time profiles and contrasted with published rifampin PK data in human adults and children. Results indicated significant similarities in dose-normalized absorption and elimination parameters between pigs and humans. Moreover, ontogenic changes observed in porcine PK parameters were consistent with ontogenic changes reported for human PK. These results demonstrate the potential utility of the juvenile porcine model for predicting human pediatric PK for rifampin. Furthermore, utilization of juvenile pigs during formulation testing may provide an alternative approach to expedite reformulation efforts during pediatric drug development.
Subject(s)
Chemistry, Pharmaceutical/methods , Drug Evaluation, Preclinical/methods , Models, Animal , Rifampin/pharmacokinetics , Administration, Oral , Age Factors , Animals , Biomarkers/blood , Dogs , Haplorhini , Humans , Mice , Rats , Rifampin/administration & dosage , Rifampin/blood , Species Specificity , Sus scrofaABSTRACT
The efficacy of daptomycin, imipenem, or rifampin with fosfomycin was evaluated and compared with that of daptomycin-rifampin in a tissue cage model infection caused by methicillin-resistant Staphylococcus aureus (MRSA). Strain HUSA 304 was used. The study yielded the following results for MICs (in µg/ml): fosfomycin, 4; daptomycin, 1; imipenem, 0.25; and rifampin, 0.03. The study yielded the following results for minimum bactericidal concentration (MBC) (in µg/ml): fosfomycin, 8; daptomycin, 4; imipenem, 32; and rifampin, 0.5. Daptomycin-rifampin was confirmed as the most effective therapy against MRSA foreign-body infections. Fosfomycin combinations with high doses of daptomycin and rifampin were efficacious alternative therapies in this setting. Fosfomycin-imipenem was relatively ineffective and did not protect against resistance.
Subject(s)
Anti-Bacterial Agents/pharmacology , Daptomycin/pharmacology , Foreign-Body Reaction/drug therapy , Fosfomycin/pharmacology , Imipenem/pharmacology , Methicillin-Resistant Staphylococcus aureus/drug effects , Rifampin/pharmacology , Staphylococcal Infections/drug therapy , Animals , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/pharmacokinetics , Colony Count, Microbial , Daptomycin/blood , Daptomycin/pharmacokinetics , Disease Models, Animal , Drug Combinations , Drug Resistance, Bacterial , Foreign-Body Reaction/blood , Foreign-Body Reaction/microbiology , Fosfomycin/blood , Fosfomycin/pharmacokinetics , Imipenem/blood , Imipenem/pharmacokinetics , Methicillin-Resistant Staphylococcus aureus/growth & development , Microbial Sensitivity Tests , Rats , Rats, Wistar , Rifampin/blood , Rifampin/pharmacokinetics , Staphylococcal Infections/blood , Staphylococcal Infections/microbiologyABSTRACT
We describe a rapid screening methodology for performing pharmacokinetic (PK) studies in mice called Fast PK. In this Fast PK method, two mice were used per compound and four blood samples were collected from each mouse. The sampling times were staggered (sparse sampling) between the two mice, thus yielding complete PK profile in singlicate across eight time points. The plasma PK parameters from Fast PK were comparable to that obtained from conventional PK methods. This method has been used to rapidly screen compounds in the early stages of drug discovery and about 600 compounds have been profiled in the last 3 years, which has resulted in reduction in the usage of mice by 800 per year in compliance with the 3R principles of animal ethics. In addition, this Fast PK method can also help in evaluating the PK parameters from the same set of animals used in safety/toxicology/efficacy studies without the need for satellite groups.
Subject(s)
Drug Evaluation, Preclinical/methods , Pharmacokinetics , Administration, Intravenous , Administration, Oral , Animals , Male , Mice , Mice, Inbred BALB C , Pharmaceutical Preparations/metabolism , Rifampin/administration & dosage , Rifampin/blood , Rifampin/pharmacokineticsABSTRACT
Low antituberculosis (TB) drug levels are common, but their clinical significance remains unclear, and methods of measurement are resource intensive. Subjects initiating treatment for sputum smear-positive pulmonary TB were enrolled from Kibong'oto National TB Hospital, Tanzania, and levels of isoniazid, rifampin, ethambutol, and pyrazinamide were measured at the time of typical peak plasma concentration (C(2 h)). To evaluate the significance of the effect of observed drug levels on Mycobacterium tuberculosis growth, a plasma TB drug activity (TDA) assay was developed using the Bactec MGIT system. Time to detection of plasma-cocultured M. tuberculosis versus time to detection of control growth was defined as a TDA ratio. TDA assays were later performed using the subject's own M. tuberculosis isolate and C(2 h) plasma from the Tanzanian cohort and compared to drug levels and clinical outcomes. Sixteen subjects with a mean age of 37.8 years ± 10.7 were enrolled. Fourteen (88%) had C(2 h) rifampin levels and 11 (69%) had isoniazid levels below 90% of the lower limit of the expected range. Plasma spiked with various concentrations of antituberculosis medications found TDA assay results to be unaffected by ethambutol or pyrazinamide. Yet with a range of isoniazid and rifampin concentrations, TDA exhibited a statistically significant correlation with drug level and drug MIC, and a TDA of ~1.0 indicated the presence of multidrug-resistant TB. In Tanzania, low (≤ 2.0) TDA was significantly associated with both lower isoniazid and rifampin C(2 h) levels, and very low (≤ 1.5) TDA corresponded to a trend toward lack of cure. Study of TDA compared to additional clinical outcomes and as a therapeutic management tool is warranted.
Subject(s)
Antitubercular Agents/blood , Drug Monitoring/methods , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/growth & development , Tuberculosis, Multidrug-Resistant/drug therapy , Tuberculosis, Pulmonary/drug therapy , Tuberculosis/drug therapy , Adult , Antitubercular Agents/administration & dosage , Cohort Studies , Humans , Isoniazid/administration & dosage , Isoniazid/blood , Microbial Sensitivity Tests/standards , Middle Aged , Rifampin/administration & dosage , Rifampin/blood , Tanzania , Tuberculosis/blood , Tuberculosis/microbiology , Tuberculosis, Multidrug-Resistant/blood , Tuberculosis, Multidrug-Resistant/microbiology , Tuberculosis, Pulmonary/microbiologyABSTRACT
The influence of active fraction isolated from pods of an indigenous plant, Moringa oleifera (MoAF) was studied on the pharmacokinetic profile of the orally administered frontline anti-tuberculosis drug rifampicin (20 mg/kg b.w.) in Swiss albino mice. The antibiotic rifampicin alone and in combination with MoAF (0.1 mg/kg b.w.) was administered orally and heparanized blood samples were collected from the orbital plexus of mice for plasma separation at 0, 1, 2, 3, 4 and 5 h, post treatment. Plasma rifampicin concentration, pharmacokinetic parameters and drug metabolizing enzyme (cytochrome P-450) activity were determined. The pharmacokinetic data revealed that MoAF-treated animals had significantly increased rifampicin plasma concentration, C(max), K(el), t(½(a)), t(½(el)), K(a) and AUC as well as inhibited rifampicin-induced cytochrome P-450 activity. In conclusion, the result of this study suggested that the bioavailability-enhancing property of MoAF may help to lower the dosage level and shorten the treatment course of rifampicin.
Subject(s)
Chromatography, High Pressure Liquid/methods , Moringa oleifera/chemistry , Plant Extracts/pharmacology , Rifampin/pharmacokinetics , Animals , Area Under Curve , Biological Availability , Cytochrome P-450 Enzyme System/metabolism , Drug Evaluation, Preclinical , Drug Synergism , Female , Male , Mice , Microsomes, Liver/chemistry , Microsomes, Liver/enzymology , Rifampin/bloodABSTRACT
In a randomized controlled trial in Ghana, treatment of Mycobacterium ulcerans infection with streptomycin (SM)-rifampin (RIF) for 8 weeks was compared with treatment with SM-RIF for 4 weeks followed by treatment with RIF-clarithromycin (CLA) for 4 weeks. The extent of the interaction of RIF and CLA combined on the pharmacokinetics of the two compounds is unknown in this population and was therefore studied in a subset of patients. Patients received CLA at a dose of 7.5 mg/kg of body weight once daily, rounded to the nearest 125 mg. RIF was administered at a dose of 10 mg/kg, rounded to the nearest 150 mg. SM was given at a dose of 15 mg/kg once daily as an intramuscular injection. Plasma samples were drawn at steady state and analyzed by liquid chromatography-tandem mass spectroscopy. Pharmacokinetic parameters were calculated with the MW/Pharm (version 3.60) program. Comedication with CLA resulted in a 60% statistically nonsignificant increase in the area under the plasma concentration-time curve (AUC) for RIF of 25.8 mg x h/liter (interquartile ratio [IQR], 21.7 to 31.5 mg x h/liter), whereas the AUC of RIF was 15.2 mg x h/liter (IQR, 15.0 to 17.5 mg x h/liter) in patients comedicated with SM (P = 0.09). The median AUCs of CLA and 14-hydroxyclarithromycin (14OH-CLA) were 2.9 mg x h/liter (IQR, 1.5 to 3.8 mg x h/liter) and 8.0 mg x h/liter (IQR, 6.7 to 8.6 mg x h/liter), respectively. The median concentration of CLA was above the MIC of M. ulcerans, but that of 14OH-CLA was not. In further clinical studies, a dose of CLA of 7.5 mg/kg twice daily should be used (or with an extended-release formulation, 15 mg/kg should be used) to ensure higher levels of exposure to CLA and an increase in the time above the MIC compared to those achieved with the currently used dose of 7.5 mg/kg once daily.
Subject(s)
Buruli Ulcer/drug therapy , Clarithromycin/therapeutic use , Rifampin/therapeutic use , Antibiotics, Antitubercular/therapeutic use , Chromatography, Liquid , Clarithromycin/blood , Clarithromycin/pharmacokinetics , Humans , Microbial Sensitivity Tests , Rifampin/blood , Rifampin/pharmacokinetics , Tandem Mass SpectrometryABSTRACT
Monkeys have been proposed as an animal model to predict the magnitude of human clinical drug-drug interactions caused by CYP3A4 enzyme induction. To evaluate whether the cynomolgus monkey can be an effective in vivo model, human CYP3A4 inducers were evaluated both in vitro and in vivo. First, a full-length pregnane X receptor (PXR) was cloned from the cynomolgus monkey, and the sequence was compared with those of rhesus monkey and human PXR. Cynomolgus and rhesus monkey PXR differed by only one amino acid (A68V), and both were highly homologous to human PXR (approximately 96%). When the transactivation profiles of 30 compounds, including known inducers of CYP3A4, were compared between cynomolgus and human PXR, a high degree of correlation with EC(50) values was observed. These results suggest that cynomolgus and human PXR respond in a similar fashion to these ligands. Second, two known human CYP3A4 inducers, rifampicin and hyperforin, were tested in monkey and human primary hepatocytes for induction of CYP3A enzymes. Both monkey and human hepatocytes responded similarly to the inducers and resulted in increased RNA and enzyme activity changes of CYP3A8 and CYP3A4, respectively. Lastly, in vivo induction of CYP3A8 by rifampicin and hyperforin was shown by significant reductions of midazolam exposure that were comparable with those in humans. These results show that the cynomolgus monkey can be a predictive in vivo animal model of PXR-mediated induction of human CYP3A4 and can provide a useful assessment of the resulting pharmacokinetic changes of affected drugs.
Subject(s)
Cytochrome P-450 CYP3A/biosynthesis , Hepatocytes/metabolism , Macaca fascicularis , Receptors, Steroid/metabolism , Xenobiotics/pharmacokinetics , Adult , Amino Acid Sequence , Animals , Bridged Bicyclo Compounds/blood , Bridged Bicyclo Compounds/pharmacokinetics , Bridged Bicyclo Compounds/pharmacology , Cell Line , Cell Line, Tumor , Cell Survival/drug effects , Cloning, Molecular , Cytochrome P-450 CYP3A/genetics , Cytochrome P-450 CYP3A/metabolism , Drug Interactions/genetics , Enzyme Induction/drug effects , Enzyme Induction/genetics , Female , Gene Expression/drug effects , Gene Expression/genetics , Hepatocytes/drug effects , Hepatocytes/enzymology , Humans , Hypericum/chemistry , Macaca mulatta , Male , Midazolam/blood , Midazolam/metabolism , Midazolam/pharmacokinetics , Middle Aged , Models, Animal , Molecular Sequence Data , Phloroglucinol/analogs & derivatives , Phloroglucinol/blood , Phloroglucinol/pharmacokinetics , Phloroglucinol/pharmacology , Plant Extracts/blood , Plant Extracts/pharmacokinetics , Pregnane X Receptor , Receptors, Steroid/genetics , Rifampin/blood , Rifampin/pharmacokinetics , Rifampin/pharmacology , Sequence Homology, Amino Acid , Terpenes/blood , Terpenes/pharmacokinetics , Terpenes/pharmacology , Transcriptional Activation/drug effects , Transcriptional Activation/genetics , TransfectionABSTRACT
The bioavailability of rifampicin (RIF) in a fixed dose combination (FDC) used for the treatment of tuberculosis remains an area of clinical concern and several pharmaceutical alternatives are being explored to overcome this problem. The present study presents a pharmacological approach in which the bioavailability of a drug may be modulated by utilizing the herb-drug synergism. The pharmacokinetic interaction of some herbal products and a pure molecule isolated from Cuminum cyminum with RIF is shown in this paper. An aqueous extract derived from cumin seeds produced a significant enhancement of RIF levels in rat plasma. This activity was found to be due to a flavonoid glycoside, 3',5-dihydroxyflavone 7-O-beta-D-galacturonide 4'-O-beta-D-glucopyranoside (CC-I). CC-I enhanced the Cmax by 35% and AUC by 53% of RIF. The altered bioavailability profile of RIF could be attributed to a permeation enhancing effect of this glycoside.
Subject(s)
Antibiotics, Antitubercular/pharmacokinetics , Cuminum/chemistry , Flavonoids/pharmacology , Glucosides/pharmacology , Rifampin/pharmacokinetics , Animals , Antibiotics, Antitubercular/blood , Biological Availability , Cell Membrane/drug effects , Drug Synergism , Female , Flavonoids/chemistry , Glucosides/chemistry , Intestinal Mucosa/drug effects , Male , Plant Extracts/pharmacology , Plants, Medicinal/chemistry , Rats , Rats, Wistar , Rifampin/bloodABSTRACT
Antimicrobial efficacy in orthopedic device infections is diminished because of bacterial biofilms which express tolerance to antibiotics. Recently, the use of high doses of levofloxacin with rifampin has been recommended for staphylococcal infections. In the present study, we evaluated the efficacy of levofloxacin at doses of 50 mg/kg/day and 100 mg/kg/day (mimicking the usual and high human doses of 500 mg/day and 750 to 1,000 mg/day, respectively) and compared it to that of to linezolid, cloxacillin, vancomycin, and rifampin in a rat tissue cage model of experimental foreign-body infection by Staphylococcus aureus. The antimicrobial efficacy in vitro (by MIC, minimum bactericidal concentration, and kill curves) for logarithmic- and stationary-phase bacteria was compared with the in vivo efficacy. In vitro bactericidal activity at clinically relevant concentrations was reached by all drugs except rifampin and linezolid in the log-phase studies but only by levofloxacin in the stationary-phase studies. The bacterial count decreases from in vivo tissue cage fluids (means) for levofloxacin at 50 and 100 mg/kg/day, rifampin, cloxacillin, vancomycin, linezolid, and controls, respectively, were: -1.24, -2.26, -2.1, -1.56, -1.47, -1.15, and 0.33 (all groups versus controls, P < 0.05). Levofloxacin at 100 mg/kg/day (area under the concentration-time curve/MIC ratio, 234) was the most active therapy (P = 0.03 versus linezolid). Overall, in vivo efficacy was better predicted by stationary-phase studies, in which it reached a high correlation coefficient even if the rifampin group was excluded (r = 0.96; P < 0.05). Our results, including in vitro studies with nongrowing bacteria, pharmacodynamic parameters, and antimicrobial efficacy in experimental infection, provide good evidence to support the use of levofloxacin at high doses (750 to 1,000 mg/day), as recently recommended for treating patients with orthopedic prosthesis infections.
Subject(s)
Anti-Bacterial Agents/pharmacology , Foreign-Body Reaction , Levofloxacin , Methicillin/pharmacology , Ofloxacin/pharmacology , Staphylococcus aureus/drug effects , Acetamides/blood , Acetamides/pharmacokinetics , Acetamides/pharmacology , Acetamides/therapeutic use , Animals , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/therapeutic use , Anti-Infective Agents/blood , Anti-Infective Agents/pharmacokinetics , Anti-Infective Agents/pharmacology , Anti-Infective Agents/therapeutic use , Cloxacillin/blood , Cloxacillin/pharmacokinetics , Cloxacillin/pharmacology , Cloxacillin/therapeutic use , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Foreign-Body Reaction/drug therapy , Foreign-Body Reaction/prevention & control , Humans , Linezolid , Male , Methicillin/blood , Methicillin/pharmacokinetics , Microbial Sensitivity Tests , Ofloxacin/blood , Ofloxacin/pharmacokinetics , Ofloxacin/therapeutic use , Oxazolidinones/blood , Oxazolidinones/pharmacokinetics , Oxazolidinones/pharmacology , Oxazolidinones/therapeutic use , Rats , Rats, Wistar , Rifampin/blood , Rifampin/pharmacokinetics , Rifampin/pharmacology , Rifampin/therapeutic use , Staphylococcal Infections/drug therapy , Staphylococcal Infections/prevention & control , Vancomycin/blood , Vancomycin/pharmacokinetics , Vancomycin/pharmacology , Vancomycin/therapeutic useABSTRACT
AIM: To study the effect of oral administration of crude aqueous extract of garlic for 14 days on pharmacokinetic parameters of isoniazid and rifampicin. MATERIALS AND METHODS: Crude extract was prepared according to the method described by Fromtling and Bulmer. The study was done on 16 New Zealand white rabbits, divided into two groups of 8 animals each for two drugs. Baseline pharmacokinetic parameters for single-dose isoniazid and rifampicin were calculated from plasma drug concentrations obtained at various time intervals after dosing. The animals were given garlic extract orally for 14 days. Pharmacokinetic parameters were calculated again as done previously. OBSERVATIONS: Administration of crude aqueous extract of garlic significantly altered the pharmacokinetic parameters for isoniazid. C(max) was reduced from 15.4 +/- 5.6 to 5.4 +/- 3.3 microg/ml. AUC((0-24)) was reduced from 76.7 +/- 25.0 to 34.3 +/- 19.2 microg/ml.h. No significant change in T(max), k(el) and AUC((0-)(alpha)) was seen. Pharmacokinetic parameters of rifampicin were not significantly altered by administration of garlic extract. CONCLUSIONS: Oral administration of garlic extract decreased the bioavailability of isoniazid significantly with no change in rate of elimination. Bioavailability of rifampicin is not significantly altered by garlic extract.
Subject(s)
Antitubercular Agents/pharmacokinetics , Garlic/chemistry , Herb-Drug Interactions , Isoniazid/pharmacokinetics , Rifampin/pharmacokinetics , Administration, Oral , Animals , Antitubercular Agents/blood , Isoniazid/blood , Plant Extracts/pharmacology , Rabbits , Rifampin/bloodABSTRACT
We evaluated the activities of quinupristin-dalfopristin (Q-D), alone or in combination with rifampin, against three strains of Staphylococcus aureus susceptible to rifampin (MIC, 0.06 microg/ml) and to Q-D (MICs, 0.5 to 1 microg/ml) but displaying various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics: S. aureus HM1054 was susceptible to quinupristin and dalfopristin (MICs of 8 and 4 microg/ml, respectively); for S. aureus RP13, the MIC of dalfopristin was high (MICs of quinupristin and dalfopristin for strain RP13, 8 and 32 microg/ml, respectively); and S. aureus HM1054R was obtained after conjugative transfer of macrolide-lincosamide-streptogramin B constitutive resistance to HM1054, and the MIC of quinupristin for this strain was high (MICs of quinupristin and dalfopristin, 64 and 4 microg/ml, respectively). In vitro time-kill curve studies showed an additive effect [corrected] between Q-D and rifampin, at a concentration of four times the MIC, against the three strains. Rabbits with aortic endocarditis were treated 4 days with Q-D, rifampin, or their combination. In vivo, the combination was highly bactericidal and synergistic against strains susceptible to quinupristin (HM1054 and RP13) and sterilized 94% of the animals. In contrast, the combination was neither synergistic nor bactericidal against the quinupristin-resistant strain (HM1054R) and did not prevent the emergence of mutants resistant to rifampin. We conclude that the in vivo synergistic and bactericidal activity of the combination of Q-D and rifampin against S. aureus is predicted by the absence of resistance to quinupristin but not by in vitro combination studies.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Drug Therapy, Combination/therapeutic use , Endocarditis, Bacterial/drug therapy , Macrolides , Rifampin/therapeutic use , Staphylococcal Infections/drug therapy , Virginiamycin/therapeutic use , Animals , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/pharmacology , Drug Resistance, Microbial , Drug Synergism , Drug Therapy, Combination/blood , Drug Therapy, Combination/pharmacology , Endocarditis, Bacterial/blood , Female , Kinetics , Lincosamides , Microbial Sensitivity Tests , Mutation , Phenotype , Rabbits , Rifampin/blood , Rifampin/pharmacology , Staphylococcal Infections/blood , Staphylococcus aureus/drug effects , Staphylococcus aureus/genetics , Virginiamycin/blood , Virginiamycin/pharmacologyABSTRACT
In the present study, Diabecon (D-400), a herbomineral anti-diabetic preparation, was studied for its pharmacokinetic interaction with the commonly used drugs rifampicin and nifedipine. Interaction of Diabecon with rifampicin: The pharmacokinetic interaction of rifampicin and Diabecon (D-400) was studied in animal models as well as in healthy human volunteers. Twelve rabbits were divided into two groups of six each. Animals in group I were treated with rifampicin (100 mg/kg body weight, p.o.) and group II with rifampicin (100 mg/kg body weight, p.o.) and Diabecon (D-400) (1 g/kg body weight, p.o.) for a period of 8 days. Rifampicin levels in plasma were estimated on day 1 and day 8 at 2, 4, 6 and 8 h after drug administration. On the basis of these findings, a clinical study in 9 healthy human volunteers aged 25-35 years and weighing 50-75 kg was initiated. They were given 450 mg of rifampicin once only on day 1 and from the second day onwards were given 2 tablets of Diabecon (D-400) twice daily for 7 days. On day 9, another dose of rifampicin (450 mg) was given along with 2 tablets of Diabecon (D-400). Blood samples were collected at 2, 4, 6 and 8 h after drug administration on day 1 and day 9 to estimate the rifampicin levels in plasma. Interaction of Diabecon with nifedipine: In another study, 12 rabbits were divided into two groups of 6 each. Group I animals were treated with nifedipine (2.5 mg/kg body weight, p.o.) and Group II animals were treated with nifedipine (2.5 mg/kg body weight, p.o.) and Diabecon (D-400) (1 g/kg body weight, p.o.) for a period of 8 days. On day 1 and day 8, blood samples were collected at 1, 2, 4 and 6 h after drug administration and plasma nifedipine levels were estimated. The results of these three studies revealed that Diabecon (D-400) did not alter the pharmacokinetic profiles of rifampicin and nifedipine.
Subject(s)
Hypoglycemic Agents/pharmacology , Nifedipine/blood , Plant Extracts/pharmacology , Rifampin/blood , Adult , Animals , Drug Interactions , Humans , Male , Phytotherapy , RabbitsABSTRACT
The effect of single and multiple doses of a herbal preparation trikatu, an Ayurvedic prescription, on the bioavailability and pharmacokinetics of rifampicin was studied in rabbits. Rabbits (n = 10) were administered a single dose of rifampicin (24 mg/kg, p.o.) alone or in combination with a single dose of trikatu (500 mg/kg, p.o.). The study had a cross over design with a washout period of 7 days. In the other study, six rabbits were administered a single dose of rifampicin (24 mg/kg, p.o.) before and after multiple doses of trikatu (500 mg/kg x 7d, p.o.). In both studies, blood samples were collected at 0, 0.5, 1, 1.5, 2, 4, 6, 9 and 12 h after drug administration and assayed for rifampicin. In animals treated with single dose of trikatu there was a significant decrease in the peak plasma concentration (Cmax) of rifampicin (P < 0.05). Multiple doses of trikatu also reduced the Cmax and delayed the Tmax of rifampicin although not to a statistically significant level. Other pharmacokinetic parameters of rifampicin were not significantly altered. Our results suggest that coadministration of trikatu does not influence the extent of bioavailability (AUC0-infinity) but reduces the rate of bioavailability (Cmax) of rifampicin. And this latter effect may reduce the efficacy of rifampicin therapy.
Subject(s)
Plant Extracts/pharmacology , Rifampin/blood , Animals , Biological Availability , Drug Interactions , Male , Medicine, Ayurvedic , Rabbits , Time FactorsABSTRACT
We studied the efficacies of ofloxacin, rifampin, and clindamycin in a Staphylococcus aureus abscess model and seven antimicrobial regimens in an intracellular killing assay. Ofloxacin plus rifampin was the most effective regimen in the abscess model, and rifampin and ofloxacin were the most active regimens in the intracellular killing assay.